Cannabics Pharmaceuticals Announces New Company Logo, New Website, and New Company Layout
TEL AVIV, Israel and BETHESDA, Maryland, September 30, 2021 / PRNewswire / – Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a world leader in the development of cannabinoid-based drugs linked to cancer and a pioneer in the development of psychedelic-inspired drugs, today announced that it has put updated its brand image with a new logo and new website. In addition, the company announced that a new corporate presentation is now available on its new website.
These updates more fully reflect the company’s strategic shift from a preclinical stage company to a clinical stage development company focused primarily on FDA regulatory compliance.
The updated site, www.cannabics.com, provides current information on each of the Company’s drug candidates and their corresponding clinical pathways. As always, the site features current news and investor information, including press releases, SEC filings, and the recently updated company presentation with the latest information on cannabis development.
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a US public company and a world leader in the development of cannabinoid drugs related to cancer. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals, follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn and on Instagram @Cannabics_Pharmaceuticals.
Recent expansion of the Cannabics Pharmaceuticals Advisory Board to include: Teacher. Caroline robert (MD, Ph.D.), melanoma specialist, and, Dr. Sigal Tavor (MD), expert in hematology, with Pr. Amos Toren (MD), Pr. Zamir Halpern (MD), Pr. Noam shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr Tal Mofkadi (Ph.D.).
Certain statements contained in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other US federal securities laws. Such statements include, but are not limited to, statements identified by words such as “believes”, “expects”, “anticipates”, “believes”, “intends”, “plans” , “Targets”, “projects” and similar expressions. The statements contained in this press release are based on the current beliefs and expectations of the management of our company and are subject to significant risks and uncertainties. Actual results may differ from those described in forward-looking statements. There are many factors that could cause or contribute to such differences, including, but not limited to the results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive product, our ability to license and protect our intellectual property. , our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any government review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our last 10-Q report filed on July 14, 2021. We do not undertake to update update any forward-looking statement or information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information concerning Cannabics Pharmaceuticals Inc., which are tolerated by the Company, must come from the Company itself and bear our name as the source.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cannabics-announces-new-corporate-logo-new-website-and-new-company-presentation-301388844.html
SOURCE Cannabics Pharmaceuticals Inc.